Daewon Pharmaceutical Launches Triple Combination Diabetes Treatment 'Dapagliflozin Extended-Release Tablets'

4 Capacity Product Lineup

Daewon Pharmaceutical announced on the 29th that it will newly launch four dosage products of 'Dapasita EM Extended-Release Tablets (active ingredients dapagliflozin, sitagliptin, metformin),' a triple combination drug for diabetes.

Daewon Pharmaceutical's triple combination diabetes treatment Dapacitam Extended-Release Tablets. [Photo by Daewon Pharmaceutical]

Daewon Pharmaceutical explained that this is the first time a triple combination drug including metformin has been approved. Since the expansion and application of the reimbursement criteria for combination diabetes treatments began in April, pharmaceutical companies have been preparing to launch combination drugs of dipeptidyl peptidase (DPP)-4 inhibitors and sodium-glucose co-transporter (SGLT)-2 inhibitors.

Dapasita EM Extended-Release Tablets 10/100/1000 mg, despite being a triple combination diabetes drug, have been released in a size similar to existing dual combination diabetes drugs to enhance ease of administration. Additionally, considering the convenience of patients who prefer smaller pills, a lower dosage and smaller-sized Dapasita EM Extended-Release Tablets 5/50/500 mg with the same combination were also launched.

Furthermore, Daewon Pharmaceutical has obtained approval for a total of four dosages of the triple combination drug, including Dapasita EM Extended-Release Tablets 5/50/750 mg and 5/50 mg, and has also launched dual combination drugs such as Dapasita Tablets 10/100 mg. Daewon Pharmaceutical explained that with the Dapasita family consisting of five options, it can provide various options based on the complementary mechanisms of SGLT-2 inhibitors and DPP-4 inhibitors.

A Daewon Pharmaceutical official stated, "The triple combination including metformin allows diabetes treatment with just one pill, which is considered revolutionary in terms of ease of administration, and initial combination therapy and early combination therapy are emphasized in diabetes treatment guidelines." He added, "We expect the Dapasita family, which directly manufactures all dosages to ensure stable supply and offers various treatment options based on high-level technology, to establish itself as an excellent treatment for diabetes patients."

Meanwhile, it is known that there are about 6 million diabetes patients in Korea, and including those in the pre-diabetes stage, more than 20 million people are exposed to the risk of diabetes. The domestic diabetes treatment market is estimated to be worth 1.3 trillion KRW.

This content was produced with the assistance of AI translation services.